JP6134739B2 - ビャクダン油およびクロストリジウム感染症に関連するその使用 - Google Patents

ビャクダン油およびクロストリジウム感染症に関連するその使用 Download PDF

Info

Publication number
JP6134739B2
JP6134739B2 JP2014553530A JP2014553530A JP6134739B2 JP 6134739 B2 JP6134739 B2 JP 6134739B2 JP 2014553530 A JP2014553530 A JP 2014553530A JP 2014553530 A JP2014553530 A JP 2014553530A JP 6134739 B2 JP6134739 B2 JP 6134739B2
Authority
JP
Japan
Prior art keywords
composition
infection
subject
sandalwood oil
clostridial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014553530A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505540A5 (https=
JP2015505540A (ja
Inventor
イアン クレメンツ，
イアン クレメンツ，
ポール カステラ，
ポール カステラ，
コーリー リベンソン，
コーリー リベンソン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANTALIS PHARMACEUTICALS Inc
Original Assignee
SANTALIS PHARMACEUTICALS Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SANTALIS PHARMACEUTICALS Inc filed Critical SANTALIS PHARMACEUTICALS Inc
Publication of JP2015505540A publication Critical patent/JP2015505540A/ja
Publication of JP2015505540A5 publication Critical patent/JP2015505540A5/ja
Application granted granted Critical
Publication of JP6134739B2 publication Critical patent/JP6134739B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N65/00—Biocides, pest repellants or attractants, or plant growth regulators containing material from algae, lichens, bryophyta, multi-cellular fungi or plants, or extracts thereof
    • A01N65/08—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Plant Pathology (AREA)
  • Agronomy & Crop Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014553530A 2012-01-23 2013-01-23 ビャクダン油およびクロストリジウム感染症に関連するその使用 Expired - Fee Related JP6134739B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261589601P 2012-01-23 2012-01-23
US61/589,601 2012-01-23
PCT/US2013/022743 WO2013112582A1 (en) 2012-01-23 2013-01-23 Sandalwood oil and its uses related to clostridium infections

Publications (3)

Publication Number Publication Date
JP2015505540A JP2015505540A (ja) 2015-02-23
JP2015505540A5 JP2015505540A5 (https=) 2015-12-24
JP6134739B2 true JP6134739B2 (ja) 2017-05-24

Family

ID=48873861

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014553530A Expired - Fee Related JP6134739B2 (ja) 2012-01-23 2013-01-23 ビャクダン油およびクロストリジウム感染症に関連するその使用

Country Status (6)

Country Link
US (2) US9579354B2 (https=)
EP (1) EP2806882B1 (https=)
JP (1) JP6134739B2 (https=)
AU (1) AU2013212264B2 (https=)
CA (1) CA2862483A1 (https=)
WO (1) WO2013112582A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140154342A1 (en) * 2011-07-28 2014-06-05 Santalis Pharmaceuticals Inc. Sandalwood oil and its uses related to skin disorders
US9861670B2 (en) 2013-03-13 2018-01-09 Santalis Healthcare Corporation Stabilized cream formulations comprising sandalwood oil
JP2018529752A (ja) 2015-10-07 2018-10-11 サンタリス ファーマシューティカルズ インコーポレイテッド サンダルウッド油及び口腔粘膜炎に関連するその用途
BR112019018861A2 (pt) 2017-03-08 2023-10-10 Hope Medical Entpr Inc Dba Hope Pharmaceuticals Uso de nitrito de sódio, método para manter os níveis fisiológicos de nitrito, prevenir enfarte do miocárdio, prevenir morte súbita cardíaca, prevenir acidente vascular cerebral, doenças cardiovasculares, pressão alta, solução aquosa
IL268883B (en) 2017-03-08 2022-09-01 Hope Medical Entpr Inc Dba Hope Pharmaceuticals Intradialytic use of sodium thiosulfate
EP3836947A4 (en) * 2018-08-17 2022-04-20 Universidad Andres Bello METHOD AND PHARMACOLOGICAL COMPOSITION FOR THE PREVENTION OF RECURRING INFECTIONS CAUSED BY CLOSTRIDIUM DIFFICILE
CN111544353A (zh) * 2020-05-21 2020-08-18 天津芸熙生物技术有限公司 一种抑菌口腔喷雾剂及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0779819A1 (en) 1994-09-06 1997-06-25 Galagen Inc. Therapeutic treatment of clostridium difficile associated diseases
GB0414886D0 (en) 2004-07-02 2004-08-04 Neutec Pharma Plc Treatment of bacterial infections
JP2006124296A (ja) 2004-10-27 2006-05-18 Tomihiko Higuchi ヘリコバクター・ピロリ菌感染症治療のための医薬組成物
US7858126B2 (en) * 2006-08-31 2010-12-28 Trinity Laboratories Inc. Derivatives of sandalwood oil and santalols for treating cold sores and herpes
WO2009014781A2 (en) 2007-05-02 2009-01-29 Nucryst Pharmaceuticals Corp. Metal-containing materials for treatment of bacterial conditions
WO2011109411A2 (en) 2010-03-01 2011-09-09 Santalis Pharmaceuticals Inc. Sandalwood oil and its uses
US8986697B2 (en) 2010-04-15 2015-03-24 Progenics Pharmaceuticals, Inc. Antibodies for the treatment of Clostridium difficile-associated infection and disease
MX2012013372A (es) 2010-05-18 2013-05-01 Optimer Pharmaceuticals Inc Metodos para tratar infecciones bacterianas recurrentes.
EP2613802A4 (en) * 2010-09-10 2014-03-26 Viropharma Inc ENVIRONMENTAL CLOSTRIDAL BACTERIOTHERAPY AND ASSOCIATED FORMULATIONS AND METHODS OF MAKING AND USING SAME

Also Published As

Publication number Publication date
EP2806882B1 (en) 2018-11-14
EP2806882A4 (en) 2015-08-05
WO2013112582A1 (en) 2013-08-01
AU2013212264B2 (en) 2017-05-18
US20170128509A1 (en) 2017-05-11
US10322154B2 (en) 2019-06-18
AU2013212264A1 (en) 2014-08-07
US20150238551A1 (en) 2015-08-27
EP2806882A1 (en) 2014-12-03
JP2015505540A (ja) 2015-02-23
CA2862483A1 (en) 2013-08-01
US9579354B2 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
JP6134739B2 (ja) ビャクダン油およびクロストリジウム感染症に関連するその使用
Bolder et al. The effect of flavophospholipol (Flavomycin) and salinomycin sodium (Sacox) on the excretion of Clostridium perfringens, Salmonella enteritidis, and Campylobacter jejuni in broilers after experimental infection
US8318152B2 (en) Effects of probiotics on humans and animals under environmental or biological changes
Alexopoulos et al. Field evaluation of a bioregulator containing live Bacillus cereus spores on health status and performance of sows and their litters
EP3444330B1 (en) Strain of genus agathobaculum having effects of preventing or treating degenerative brain diseases, and use thereof
US20180028490A1 (en) Methods Of Treating Diarrhea And Promoting Intestinal Health In Non-Human Animals
UA97078C2 (uk) Фармацевтична композиція інгібітора протонної помпи і пребіотика для лікування виразкових уражень шлунка й дванадцятипалої кишки
KR20210004221A (ko) 알파-망고스틴, 감마-망고스틴 또는 셀라스트롤을 포함하는 항균활성을 가진 조성물
Ströbel et al. Effects of oral supplementation of probiotic strains of Lactobacillus rhamnosus and Enterococcus faecium on diarrhoea events of foals in their first weeks of life
Aluko et al. Combined effects of chitosan and microencapsulated Enterococcus faecalis CG1. 0007 probiotic supplementation on performance and diarrhea incidences in enterotoxigenic Escherichia coli K88+ challenged piglets
Abudabos Use of a competitive exclusion product (Aviguard®) to prevent Clostridium perfringens colonization in broiler chicken under induced challenge
JP2014133736A (ja) 腸絨毛伸長組成物及び抗コクシジウム組成物
US20170100429A1 (en) Methods of Treating Diarrhea in Neonatal and Young Non-Human Animals
Aktas et al. Efficacy of Saccharomyces boulardii as a probiotic in dogs
US11607433B2 (en) Composition for preventing, improving, or treating autism spectrum disorders including Agathobaculum sp. strain as active ingredient
Meshram et al. Treatment of clinical cases of bacterial enteritis in goat with new polyherbal antidiarrhoeal formulation
KR20150024116A (ko) 바실러스 속, 락토바실러스 속, 이스트 속 및 파지 혼합물을 유효성분으로 함유하는 축산용 프로바이오틱스 조성물
RU2415684C2 (ru) Фармацевтическая композиция для лечения и/или профилактики дисбиозов кишечника в процессе проведения антибактериальной терапии у теплокровных животных: крупного рогатого скота, свиней, домашних животных, в частности собак, кошек, и сельскохозяйственных птиц и способ лечения и/или профилактики дисбиозов кишечника в процессе проведения антибактериальной терапии у теплокровных животных: крупного рогатого скота, свиней, домашних животных, в частности собак, кошек, и сельскохозяйственных птиц
RU2786335C1 (ru) Способ лечения болезней бактериальной этиологии у животных
KR102208837B1 (ko) 메틸 갈레이트 및 플로로퀴놀론 계열 항균제를 포함하는 박테리아의 장 부착, 침입 억제, 또는 항생제 내성 억제용 조성물
MXPA04012137A (es) Bacteriana novedosa para tratamiento de enfermedad.
JP2696186B2 (ja) クリプトストリジウム症治療剤
RU2391992C1 (ru) Способ профилактики и лечения криптоспоридиоза телят
WO2023161847A1 (en) Trans-species transplantation of gut microbiota
Ripac-Labor et al. Spotty liver disease in poultry

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151104

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160816

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170116

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170327

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170424

R150 Certificate of patent or registration of utility model

Ref document number: 6134739

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees